Global Age-Related Macular Degeneration Market Analysis 2025–2029: Opportunities for Strategic Growth

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Age-Related Macular Degeneration Market Expected To Become By 2029 Compared With Its 2025 Level?

The market size for age-related macular degeneration has experienced substantial growth in recent years. It is projected to increase from $9.96 billion in 2024 to $10.67 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.1%. The expansion observed historically can be ascribed to elements such as an aging population, shifts in lifestyles and environmental factors, genetic predisposition, heightened awareness and earlier diagnosis, and developments in diagnostic techniques.

The age-related macular degeneration market is poised for significant expansion in the coming years. By 2029, its valuation is projected to reach $14.29 billion, expanding at a compound annual growth rate (CAGR) of 7.6%. Factors contributing to this growth during the forecast period include advancements in genetics and biomarkers research, the development of new therapeutic approaches, the rise of telemedicine and remote monitoring, and increased patient advocacy and educational initiatives. Key trends anticipated during this period encompass personalized medicine strategies, breakthroughs in retinal imaging technologies, the introduction of sustained drug delivery systems, ongoing clinical trials for experimental treatments, and strengthened collaborations for research and development efforts.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10845&type=smp

Which Major Market Drivers Are Shaping The Future Of The Age-Related Macular Degeneration Market?

The increasing prevalence of age-related macular degeneration (AMD) is projected to drive the growth of the age-related macular degeneration (AMD) market in the future. Age-related macular degeneration (AMD) is a progressive eye condition that affects the macula, a small part of the retina essential for central vision. Treatments for age-related macular degeneration (AMD) help patients suffering from retinal disorders by reducing the severity of the disease. For instance, in February 2023, reports from Optimaxa., a UK-based laser eye treatment specialist, indicated that age-related macular degeneration (AMD) affected 196 million individuals globally and is expected to reach 288 million by 2040, accounting for 8.7 percent of the world’s population. Therefore, the rising prevalence of age-related macular degeneration (AMD) is a key driver for the age-related macular degeneration (AMD) market.

What Are The Segment Types Shaping The Age-Related Macular Degeneration Market?

The age-related macular degenerationmarket covered in this report is segmented –

1) By Type: Wet Age-Related Macular Degeneration (AMD); Dry Age-Related Macular Degeneration (AMD)

2) By Drug: Eylea; Lucentis; Avastin; Other Products

3) By Route Of Administration: Intravenous; Intravitreal

4) By Distribution Channel: Hospital Pharmacy; Specialty Pharmacy; Online Pharmacy

Subsegments:

1) By Wet Age-Related Macular Degeneration (AMD): Anti-VEGF Injections; Photodynamic Therapy; Laser Surgery

2) By Dry Age-Related Macular Degeneration (AMD): Nutritional Supplements; Low Vision Aids; Therapies For Geographic Atrophy

How Are Trends Influencing The Age-Related Macular Degeneration Market?

Leading companies in the age-related macular degeneration (AMD) market are developing innovative therapies, such as bispecific antibodies, aimed at reducing treatment frequency. A bispecific antibody is an engineered antibody capable of binding to two distinct antigens concurrently. For instance, in May 2022, Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, introduced Vabysmo intravitreal injection 120 mg/mL, a bispecific antibody designed for treating eye conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). This groundbreaking therapy functions by simultaneously targeting two essential pathways: angiopoietin-2 (Ang-2), which contributes to abnormal blood vessel growth and inflammation, and Vascular Endothelial Growth Factor-A (VEGF-A), a major factor in the formation of new blood vessels that can lead to vision loss. A key benefit of Vabysmo is its extended dosing intervals, allowing treatments to be administered every 16 weeks, which improves patient convenience and adherence. Its dual-action approach signifies considerable progress in ophthalmic treatments, effectively addressing the urgent requirement for reliable therapies in retinal diseases.

Who Are The Primary Competitors In The Global Age-Related Macular Degeneration Market?

Major companies operating in the age-related macular degeneration market include F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Amgen Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., AbbVie Inc., Outlook Therapeutics Inc., Biogen Inc., Samsung Bioepis Co. Ltd., Biocon Ltd., Bio-Thera Biopharmaceutical Co. Ltd., AstraZeneca plc, Acucela Inc., Ophthotech Corporation, Kodiak Sciences Inc., REGENXBIO Inc., Alkahest Inc., Opthea Limited, Apellis Pharmaceuticals Inc., Graybug Vision Inc., IVERIC bio Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., Tyrogenex Inc., Chengdu Kanghong Pharmaceutical Group Co. Ltd., I-Mab Biopharma Co. Ltd., pSivida Corp., Clearside Biomedical Inc., SciFluor Life Sciences LLC, Lineage Cell Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/age-related-macular-degeneration-global-market-report

Which Geographies Are Emerging As Strong Markets For The Age-Related Macular Degeneration Industry?

North America was the largest region in the global age-related macular degeneration market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the age-related macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Age-Related Macular Degeneration Market Report:

https://www.thebusinessresearchcompany.com/customise?id=10845&type=smp

Browse Through More Reports Similar to the Global Age-Related Macular Degeneration Market 2025, By The Business Research Company

Macular Degeneration Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

Dry Eye Medication Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dry-eye-medication-global-market-report

Eyewear Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/eyewear-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795